These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8782740)

  • 61. Processing of bacterial antigens for presentation to class I and II MHC-restricted T lymphocytes.
    Harding CV; Song R; Griffin J; France J; Wick MJ; Pfeifer JD; Geuze HJ
    Infect Agents Dis; 1995 Mar; 4(1):1-12. PubMed ID: 7728352
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications.
    Afridi S; Hoessli DC; Hameed MW
    Immunol Rev; 2016 Jul; 272(1):151-68. PubMed ID: 27319349
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest?
    Kropshofer H; Hämmerling GJ; Vogt AB
    Immunol Today; 1997 Feb; 18(2):77-82. PubMed ID: 9057358
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Expression and function of HLA-DR3 and DQ8 in transgenic mice lacking functional H2-M.
    Rajagopalan G; Smart MK; Cheng S; Krco CJ; Johnson KL; David CS
    Tissue Antigens; 2003 Aug; 62(2):149-61. PubMed ID: 12889995
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines.
    Germain RN
    Ann N Y Acad Sci; 1995 May; 754():114-25. PubMed ID: 7625645
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MHC class II-derived peptides can bind to class II molecules, including self molecules, and prevent antigen presentation.
    Rosloniec EF; Vitez LJ; Buus S; Freed JH
    J Exp Med; 1990 May; 171(5):1419-30. PubMed ID: 2332729
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
    Adams S; Humphreys RE
    Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Presentation of antigen and MHC-restricted unresponsiveness.
    Ríhová B
    Folia Biol (Praha); 1995; 41(3-4):140-62. PubMed ID: 7589711
    [No Abstract]   [Full Text] [Related]  

  • 69. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.
    Zhao W; Sher X
    PLoS Comput Biol; 2018 Nov; 14(11):e1006457. PubMed ID: 30408041
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
    Meyer zu Hörste G; Heidenreich H; Mausberg AK; Lehmann HC; ten Asbroek AL; Saavedra JT; Baas F; Hartung HP; Wiendl H; Kieseier BC
    Neurobiol Dis; 2010 Feb; 37(2):483-90. PubMed ID: 19914379
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
    Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
    Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The study of HLA class II and autoimmune diabetes.
    Wong FS; Wen L
    Curr Mol Med; 2003 Feb; 3(1):1-15. PubMed ID: 12558070
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation.
    Mosyak L; Zaller DM; Wiley DC
    Immunity; 1998 Sep; 9(3):377-83. PubMed ID: 9768757
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Present Yourself! By MHC Class I and MHC Class II Molecules.
    Rock KL; Reits E; Neefjes J
    Trends Immunol; 2016 Nov; 37(11):724-737. PubMed ID: 27614798
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 70-kDa heat shock proteins: specific interactions with HLA-DR molecules and their peptide fragments.
    Haug M; Schepp CP; Kalbacher H; Dannecker GE; Holzer U
    Eur J Immunol; 2007 Apr; 37(4):1053-63. PubMed ID: 17357109
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of MHC-Bound Peptides from Dendritic Cells Infected with Salmonella enterica Strain SL1344: Implications for a Nontyphoidal Salmonella Vaccine.
    Karunakaran KP; Yu H; Jiang X; Chan Q; Goldberg MF; Jenkins MK; Foster LJ; Brunham RC
    J Proteome Res; 2017 Jan; 16(1):298-306. PubMed ID: 27802388
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel molecules related to MHC antigens.
    Stroynowski I; Forman J
    Curr Opin Immunol; 1995 Feb; 7(1):97-102. PubMed ID: 7772287
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The unconventional role of HLA-E: The road less traveled.
    Grant EJ; Nguyen AT; Lobos CA; Szeto C; Chatzileontiadou DSM; Gras S
    Mol Immunol; 2020 Apr; 120():101-112. PubMed ID: 32113130
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands.
    Perez MAS; Bassani-Sternberg M; Coukos G; Gfeller D; Zoete V
    Front Immunol; 2019; 10():2731. PubMed ID: 31824508
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HLA3D: an integrated structure-based computational toolkit for immunotherapy.
    Li X; Lin X; Mei X; Chen P; Liu A; Liang W; Chang S; Li J
    Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35289353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.